Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): a multi-center, randomized, open-label, phase II trial
Eva Ciruelos.Patricia Villagrasa.Mafalda Oliveira, Sonia Pernas,Javier Cortés, Silvia Vazquez, Noelia Martínez,Antonia Perelló,Begoña Bermejo,Eduardo Martínez,Isabel Garau, Mireia Melé, Alvaro Montaño,Estela Vega, Blanca Cantos,María José Echarri,Tomás Pascual,Jordi Canes,Pamela Celiz,Xavier Gonzalez and Aleix Prat
Comunicaciones en congresos
TIP
SABCS
2019
PATRICIA-II
